双极止血钳与血夹±肾上腺素注射作为活动性非静脉曲张性上消化道出血初始内镜治疗的标准疗法对比:BeBop试验的前瞻性随机多中心研究方案
这是一项前瞻性、随机、多中心优效性试验方案,拟纳入活动性非静脉曲张性上消化道出血患者,1:1随机分配至标准疗法(血夹±肾上腺素注射)或实验疗法(双极止血钳),主要终点为成功初始止血及30天内无再出血的复合终点,每臂需45例。
要点
- 活动性非静脉曲张性上消化道出血患者随机接受双极止血钳或标准疗法(血夹±肾上腺素注射)。
- 主要复合终点为成功初始止血及30天内无再出血,每臂样本量45例。
- 初始治疗15分钟内失败可行交叉治疗,30分钟后允许补救治疗(如over-the-scope-clip)。
核心结论
- 研究假设双极止血钳在成功初始止血及30天内无再出血的复合终点上优于标准疗法。
- 作者认为这项随机、前瞻性、多中心研究可能有助于回答双极止血钳能否作为Forrest I a+b期非静脉曲张性上消化道出血内镜治疗的一线疗法。
研究设计与样本
- 前瞻性、随机、多中心优效性试验,中心数n≥5,患者按1:1随机分配至标准疗法组与实验疗法组。
- 每治疗臂需45例患者,以80%把握度、0.05显著性水平检验25.4%的绝对差异。
- 所有患者同时接受质子泵抑制剂标准治疗,招募期12个月。
- 试验注册号ClinicalTrials.gov NCT05353062,注册日期2022年4月30日。
关键数值与推荐
- 初始治疗15分钟内失败时首先尝试交叉治疗,30分钟后允许补救治疗(如over-the-scope-clip)。
- 主要复合终点为成功初始止血及30天内无再出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 抗凝药和/或抗血小板药物可能是统计分析中的重要混杂因素,需加以考虑并在必要时计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with active nonvariceal upper gastrointestinal bleeding (NVUGIB) usually require urgent endoscopic treatment. Standard therapy (ST) using haemoclip + / - epinephrine injection is not always successful. Bipolar haemostatic forceps (HemoStat/Pentax®) are an approved medical device for the treatment of gastrointestinal bleeding. However, their use as a primary endoscopic treatment for active NVUGIB has not yet been proven in a randomized prospective study. METHODS: This is a prospective, randomized, multicentre superiority trial (n ≥ 5). Patients with active NVUGIB will be randomized (1:1) to ST and to experimental therapy (ET) by application of bipolar haemostatic forceps. In the case of failed initial treatment within 15 min, crossover treatment will be attempted first. Rescue treatment (e.g. via over-the-scope-clip) will then be allowed after 30 min. All patients will also receive standard therapy with proton pump inhibitors. Forty-five patients per treatment arm are required to demonstrate an absolute difference of 25.4% with a power of 80% and a significance level of 0.05. DISCUSSION: The hypothesis of the study is that bipolar haemostatic forceps are superior to ST in terms of successful primary haemostasis and the absence of recurrent bleeding within 30 days (combined endpoint). The 1:1 randomization is also ethically justifiable for this study, as both procedures are approved for the intervention in question. To further increase the safety of the patients in the study, crossover treatment and rescue treatment are planned. The prospective design seems feasible in a reasonable time frame (recruitment period of 12 months), as nonvariceal upper gastrointestinal bleeding is common. Anticoagulants and/or antiplatelet drugs could be an important confounding factor in the statistical analysis that needs to be taken into account and calculated if necessary. In conclusion, this randomized, prospective, multicentre study could make an important contribution to answering the question of whether bipolar haemostatic forceps could be the first-line therapy in the endoscopic treatment of stage Forrest I a + b NVUGIB. TRIAL REGISTRATION: ClinicalTrials.gov NCT05353062. Registered on April 30 2022.
引用
- Schmitz D, Thielemann L, Grassmann F, et al. Bipolar haemostatic forceps versus standard therapy by haemoclip + / - epinephrine injection as initial endoscopic treatment in active non-variceal upper GI bleeding: study protocol for a prospective, randomized multicentre trial (BeBop-Trial). Trials. 2023. PMID: 37322511. doi:10.1186/s13063-023-07394-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。